2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-110142
    Thermopsidine 492-02-4 98%
    Thermopsidine (CC4) is a selective partial agonist at α4β2/α6β2 nAChR with EC50 values of 2.2 μM target α4β2.
    Thermopsidine
  • HY-11017R
    Rivastigmine tartrate (Standard) 129101-54-8 98%
    Rivastigmine (tartrate) (Standard) is the analytical standard of Rivastigmine (tartrate). This product is intended for research and analytical applications. Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
    Rivastigmine tartrate (Standard)
  • HY-11018R
    Risperidone (Standard) 106266-06-2 98%
    Risperidone (Standard) is the analytical standard of Risperidone. This product is intended for research and analytical applications. Risperidone is a serotonin 5-HT2 receptor blocker, P-Glycoprotein inhibitor and potent dopamine D2 receptor antagonist, with Kis of 4.8, 5.9 nM for 5-HT2A and dopamine D2 receptor, respectively.
    Risperidone (Standard)
  • HY-110194
    Virodhamine TFA 1415264-56-0 98%
    Virodhamine TFA is an endocannabinoid, it regulates neurotransmission by activating the cannabinoid (CB) receptors. Virodhamine is an antagonist of CB1 receptor and an agonist of CB2 receptor. Virodhamine TFA induces megakaryocytic differentiation by triggering MAPK signaling and ROS production. Virodhamine TFA can be used for the research of various neurological disorders such as Alzheimer's and Parkinson's diseases.
    Virodhamine TFA
  • HY-110202
    MRS5698 1377273-00-1 98%
    MRS5698 is a selective Gi protein-coupled A3 adenosine receptor (A3AR) agonist, with Kis of approximately 3 nM for human and mouse A3AR, respectively. MRS5698 can be used for the research of pain and psoriasis.
    MRS5698
  • HY-110230
    Flupirtine-d4 hydrochloride 1324717-75-0 99.87%
    Flupirtine-d4 (D 9998-d4) hydrochloride is the deuterium labeled Flupirtine hydrochloride (HY-W709349). Flupirtine hydrochloride is an orally active, blood-brain barrier-crossing non-opioid analgesic and neuroprotective agent. Flupirtine hydrochloride is a neuronal potassium channel opener (Kv7 activator), a NMDA receptor antagonist and a GABA receptor activator. Flupirtine hydrochloride stabilizes blood-brain-barrier integrity, reduces oxidative stress and brain leukocyte infiltration, enhances angioneurogenesis, suppresses calcium influx, stabilizes neuronal resting membrane potential, and counteracts focal cerebral ischemia. Flupirtine hydrochloride exhibits analgesic, muscle relaxant properties, protects neurons from excitotoxic, ischemic, or cytokine-mediated death. Flupirtine hydrochloride functions as a non-opioid analgesic without antipyretic or antiphlogistic properties, shows no relevant affinity to opiate receptor. Flupirtine hydrochloride can be used for the research of focal cerebral ischemia, pain, Alzheimer’s disease, or multiple sclerosis.
    Flupirtine-d4 hydrochloride
  • HY-110303
    Xanthine amine congener dihydrochloride 1962928-23-9 98%
    Xanthine amine congener dihydrochloride (XAC dihydrochloride) is a potent Adenosine A1 receptor and A2 receptor antagonist with IC50 values of 1.8 and 114 nM, respectively. Xanthine amine congener acts as a convulsant agent in mice model.
    Xanthine amine congener dihydrochloride
  • HY-110304
    NPEC-caged-LY379268 98%
    NPEC-caged-LY379268 is a type II mGluR agonist.
    NPEC-caged-LY379268
  • HY-110310
    NGD 98-2 hydrochloride 1780390-58-0 98%
    NGD 98-2 hydrochloride is an orally active corticotropin releasing factor-1 (CRF-1) receptor antagonist
    NGD 98-2 hydrochloride
  • HY-110330
    R 1485 dihydrochloride 98%
    R 1485 is a 5-HT6 receptor antagonist.
    R 1485 dihydrochloride
  • HY-110351
    BGC-20-1531 hydrochloride 1962928-26-2 98%
    BGC 20-1531 (PGN 1531) hydrochloride is a potent and selective prostanoid EP4 receptor antagonist, with a pKb of 7.6. BGC 20-1531 hydrochloride has the potential for the research of migraine headache.
    BGC-20-1531 hydrochloride
  • HY-110366
    WAY-181187 oxalate 1883548-85-3 98%
    WAY-181187 (SAX-187) oxalate is a potent and selective full 5-HT6 receptor agonist with a Ki of 2.2 nM and an EC50 of 6.6 nM. WAY-181187 oxalate mediates 5-HT6 receptor-dependent signal pathways, such as cAMP, Fyn and ERK1/2 kinase, as specific agonist.
    WAY-181187 oxalate
  • HY-110391
    BX-513 193542-65-3 98%
    BX-513 is a highly potent and selective CCR1 antagonist. BX-513 effectively inhibits the binding of radiolabeled MIP-1α and RANTES to CCR1, with Ki values of 40 nM and 60 nM, respectively. BX-513 suppresses MIP-1α-induced extracellular acidification, MIP-1α- and RANTES-induced intracellular calcium mobilization, as well as MIP-1α- and RANTES-induced migration of peripheral blood mononuclear cells. BX-513 can be used for the research of rheumatoid arthritis and multiple sclerosis.
    BX-513
  • HY-110411
    Chlorproethazine hydrochloride 4611-02-3 98%
    Chlorproethazine hydrochloride is an orally active phenothiazine compound. Chlorproethazine hydrochloride can eliminate spasticity when administered intravenously and also effectively reduce rigidity in decerebrate cats. Chlorproethazine hydrochloride can be used in the research of neurological diseases.
    Chlorproethazine hydrochloride
  • HY-11052A
    Trap-101 hydrochloride 1216621-00-9 98%
    Trap-101 hydrochloride is a potent, selective and competitive antagonist of NOP receptors over classical opioid receptors. Trap-101 stimulates GTPγ35S binding to CHOhNOP membranes with pKi values of 8.65, 6.60, 6.14 and <5 for NOP, μ-, κ-, and δ-opioid receptors, respectively. Trap-101 attenuates motor deficits in a rat model of parkinson's disease and can be used for the research of nervous system diseases.
    Trap-101 hydrochloride
  • HY-111000
    BNC-1 96335-59-0 98%
    BNC-1 is an Elk-1 activator that can promote phosphorylation and activation of Elk-1.
    BNC-1
  • HY-111011
    CR 665 acetate 958873-83-1 98%
    CR 665 (JNJ 38488502) acetate is a kappa-opioid agonist that may effectively treat visceral pain by activating receptors on afferent nerves within the gut. CR 665 acetate exhibits peripheral selectivity, differentiating its pharmacokinetic profile from that of non-selective opioids like oxycodone. CR 665 acetate has demonstrated a beneficial effect on visceral pain tolerance thresholds without the delayed analgesic response characteristic of opioids that penetrate the brain. CR 665 acetate is proposed for use in managing postoperative pain due to its pain-relieving properties.
    CR 665 acetate
  • HY-111025
    Ectylurea 95-04-5 98%
    Ectylurea, a N-acylurea, can be used in studies of tension and anxiety symptoms, has no effect on the autonomic nervous system, and has no convulsive, analgesic or antispasmodic activity in animals.
    Ectylurea
  • HY-111038
    Capsiconiate 946572-73-2 98%
    Capsiconiate (Coniferyl (E)-8-methyl-6-nonenoate) is a TRPV1 agonist (EC50= 3.2 μM). Capsiconiate can be used to study TRPV1-mediated diseases such as pain, inflammation, and epilepsy(EC50= 3.2 μM).
    Capsiconiate
  • HY-111051
    JN403 942606-12-4 98%
    JN403 is an orally active and selective α7 nicotinic acetylcholine receptor agonist. JN403 can be used in the study of central nervous system disorders.
    JN403
Cat. No. Product Name / Synonyms Application Reactivity